Personal tools

Sponsorname

Your company could advertise here

www.fla-consulting.eu

Document:GBR MEDDEV 2.7/3 revision 3 May-2015

From GxPlex

Revision as of 19:36, 27 June 2026 by gxplex>GxPlexBot (Import from GxPlex Excel)
Jump to: navigation, search


Document information
Reference GBR MEDDEV 2.7/3 revision 3 May-2015
Validity area GBR
Scope(s) MD
Document name MEDDEV 2.7/3 revision 3
Version / Revision May-2015
Status Current
Document type Official guideline
Language(s) EN
Description GUIDELINES ON MEDICAL DEVICES CLINICAL INVESTIGATIONS:

SERIOUS ADVERSE EVENT REPORTING UNDER DIRECTIVES 90/385/EEC AND 93/42/EEC.

Official source Official link
Restricted access No
Submitted by Florian Adragna
Contributors


References

Reference Scope Document part Language Preview
Reference:GBR MEDDEV 2.7/3 revision 3 May-2015 8 MD 8 EN 8. CAUSALITY ASSESSMENT The relationship between the use of the medical device (including the medical - surgical procedure) and the occurrence of each adverse event shall be assessed and categorized. ...
Reference:GBR MEDDEV 2.7/3 revision 3 May-2015 7.2 MD 7.2 EN 7. REPORTING TIMELINES [...] 7.2 Report by the investigator to the sponsor The sponsor shall implement and maintain a system to ensure that the reporting of the reportable events as defined under ...
Reference:GBR MEDDEV 2.7/3 revision 3 May-2015 4 MD 4 EN CLINICAL INVESTIGATIONS: SERIOUS ADVERSE EVENT REPORTING UNDER DIRECTIVES 90/385/EEC AND 93/42/EEC 4. REPORTABLE EVENTS UNDER ANNEX 7 AND ANNEX X OF DIRECTIVES 90/385/EEC AND 93/42/EEC RESPECTIVELY ...
Reference:GBR MEDDEV 2.7/3 revision 3 May-2015 5 - 6 MD 5 - 6 EN CLINICAL INVESTIGATIONS: SERIOUS ADVERSE EVENT REPORTING UNDER DIRECTIVES 90/385/EEC AND 93/42/EEC 5. REPORT BY WHOM. Reportable events have to be reported by the sponsor of the clinical ...
Reference:GBR MEDDEV 2.7/3 revision 3 May-2015 7.1 MD 7.1 EN 7. REPORTING TIMELINES 7.1 Report by sponsor to NCAs. The sponsor must report to the NCAs where the clinical investigation has commenced: - for all reportable events as described in section 4 which ...